A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B

Inclusion Criteria: * 18yrs≤age≤65yrs. * 17≤BMI(body mass index)≤28. * HBsAg positive≥6 months. * Serum HBV DNA≥20,000IU/ml, HBsAg positive and HBeAg positive at screening. * 2ULN≤ALT≤10ULN(ULN=upper limit of normal) at screening. * Pregnancy test must be negative for female patients of childbearing potential. All patients take effective birth control measures during treatment and 6 months after the treatment. * Agree to participate in the study and sign the informed consent. Exclusion Criteria: * Pregnant or lactating females * Interferon treatment history, or using nucleos(t)ide analogues for chronic hepatitis B treatment within the previous 6 months, or any evidence of nucleosi(t)ide analogues resistance . * Receiving strong immunomodulatory agents (e.g., steroids, thymosin) for more than two weeks 6 months prior to screening. * Receiving hepatotoxicity agents (e.g., aczone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than two weeks 6 months prior to screening. * Co-infected with active hepatitis A, hepatitis C, hepatitis D, and/or human immunodeficiency virus (HIV). * History or evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., autoimmune hepatitis, alcoholic liver disease, toxin exposures. * Suffering from any other acute or chronic infectious disease. * Mental disorder or physical disability, or family history of neurological and psychiatric disorders. * Neutrophil count \<1500 cells/mm3, or platelet count \<90000 cells/mm3 at screening. * Child-Pugh≥B, or other evidence of liver decompensation (e.g. serum albumin\<35g/L , prothrombin time\>3 seconds prolonged, serum bilirubin\>2ULN, prothrombin activity \<60%, history of liver decompensation). * Serum creatinine level \>ULN in screening period. * Serum creatine kinase level \>2ULN except for physiological factors (e.g., exercise). * AFP\>100ng/L. If 50ng/L\<AFP\<100ng/L at screening, retest 2 weeks later, and if AFP \<50ng/L can enrolled, vs, excluded. * Hepatocarcinoma or suffering from any other malignant tumor. * Autoimmune disease(e.g., psoriasis, systemic lupus erythematosus). * Moderate or severe hypertension, or mild hypertension without well controlled. * With not well- controlled endocrine disease (e.g., thyroid dysfunction, diabetes mellitus). * Drug abusing, or alcoholism. * HBeAb positive or HBsAb positive at screening. * Allergic to interferon, or GM-CSF, or any fragment of the study drug. * Other conditions which in the opinion of the investigator precluding enrollment into the study(e.g., low compliance).